Suppr超能文献

β受体阻滞剂在动脉高血压治疗中的作用

[Role of beta-blockers in the treatment of arterial hypertension].

作者信息

Goose P, Dallocchio M

机构信息

Service de Cardiologie, CHU, Bordeaux.

出版信息

Ann Cardiol Angeiol (Paris). 1989 Feb;38(2):115-9.

PMID:2565100
Abstract

The introduction, more than twenty years ago, of beta-blockers in the treatment of arterial hypertension, represented a significant advance. With these medications, many hypertensive patients are effectively under control and malignant hypertension is practically inexistent. Today, the treatment of hypertension is markedly improved with the development of new, active medications, while the beta-blockers family has markedly evolved. The role of beta-blockers in the treatment of hypertension, must therefore be re-evaluated according to their properties as compared to those of other classes of antihypertensive medications. Indeed, there are standard contraindications to he use of beta-blockers, sometimes resulting in adverse reactions, either clinical (fatigue, sexual disorders, vasomotor syndromes)--much less frequent with the new molecules--or biological (especially serum lipid levels), the consequences of which remains ill-defined--some beta-blockers appear practically without any harmful effect. Actually, despite these drawbacks, usually minimal, there are numerous and strong arguments in favor of the use of beta-blockers in the treatment of hypertension: 1) their significant follow-up in the treatment of hypertension; this is a well-known argument; 2) their effectiveness in hypertension, as a single drug and single daily dose; 3) their cost, which is lower than that of new anti-hypertensive medications; 4) their cardio-protective role, demonstrated by experimental data (myocardial protection and anti-arrhythmic effect in experimental ischemia), and clinical data (improvement of left ventricular hypertrophy, control of blood pressure increase during exertion and stress, secondary prevention after myocardial infarction).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

二十多年前,β受体阻滞剂被引入用于治疗动脉高血压,这代表了一个重大进展。使用这些药物后,许多高血压患者得到了有效控制,恶性高血压几乎不存在了。如今,随着新型活性药物的研发,高血压治疗有了显著改善,而β受体阻滞剂家族也有了明显演变。因此,必须根据β受体阻滞剂与其他类抗高血压药物相比的特性,重新评估其在高血压治疗中的作用。确实,使用β受体阻滞剂存在一些标准的禁忌证,有时会导致不良反应,包括临床方面的(疲劳、性功能障碍、血管舒缩综合征——新分子引发的这类反应频率低得多)或生物学方面的(尤其是血脂水平),其后果仍不明确——有些β受体阻滞剂似乎几乎没有任何有害影响。实际上,尽管存在这些通常较为轻微的缺点,但仍有许多有力论据支持在高血压治疗中使用β受体阻滞剂:1)它们在高血压治疗方面有大量随访研究;这是一个众所周知的论据;2)作为单一药物和每日单剂量,它们在高血压治疗中有效;3)它们的成本低于新型抗高血压药物;4)它们的心脏保护作用,有实验数据(实验性缺血中的心肌保护和抗心律失常作用)以及临床数据(改善左心室肥厚、控制运动和应激时血压升高、心肌梗死后的二级预防)证明。(摘要截选至250词)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验